Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENL103 in Recurrent or Refractory Multiple Myeloma
NCT06067581Phase 1Recruiting
- Sponsor
- Senlang Bio
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of senl-103 in multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoint: Number and incidence of adverse events at 1 month. Started Aug 2023; status: recruiting.
02
Drugs
senl-103
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06067581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067581.